Skip to main content
Top
Published in: Thyroid Research 1/2013

Open Access 01-12-2013 | Research

Negative correlation between bone mineral density and TSH receptor antibodies in long-term euthyroid postmenopausal women with treated Graves’ disease

Authors: Monica A Ercolano, Monica L Drnovsek, Maria C Silva Croome, Monica Moos, Ana M Fuentes, Fanny Viale, Ulla Feldt-Rasmussen, Alicia T Gauna

Published in: Thyroid Research | Issue 1/2013

Login to get access

Abstract

Background

Thyrotoxicosis is a cause of secondary osteoporosis. High concentrations of triiodotironine (T3) in Graves’ disease stimulate bone turnover, but it is unclear if euthyroidism will always normalize bone metabolism. Thyrotropin (TSH) is known to affect directly the bone metabolism through the TSH receptor and TSH receptor antibodies (TRAb) may have an important role in bone turn-over.
The aim of our study was to determine, in pre and postmenopausal euthyroidism patients with previous overt hyperthyroidism due to Graves’ disease the bone mineral density (BMD) as well as factors that could affect BMD in each group, including TRAb.

Methods

Cross-sectional, non-interventional study. Fifty-seven patients with previous hyperthyroidism due to Graves’ disease (premenopausal: 30, postmenopausal: 27) that remained euthyroid for at least 6 months prior to study were included and compared with fifty- two matched respective controls. Thyrotoxine (T4), TSH, TRAb and BMD were measured.

Results

Only euthyroid postmenopausal patients with a history of hyperthyroidism due to Graves’ disease showed lower whole body BMD than matched controls. The BMD expressed as Z-score was less in whole body and lumbar spine in postmenopausal in relation to premenopausal women with previous overt hyperthyroidism due to Graves’ disease.
In the postmenopausal patients, the Z-score of lumbar spine BMD correlated negatively with TRAb (r = −0,53, p < 0.008), positively with the time of evolution of the disease (r = +0.42, p < 0.032) and positively with the time of euthyroidism (r = + 0.50, p < 0.008), but neither with serum T4 nor TSH. In a multiple regression analysis TRAb was the only significant independent variable in relation to lumbar spine BMD (F = 3. 90, p < 0.01).

Conclusions

In euthyroid women with a history of Graves’ hyperthyroidism, BMD was only affected in the postmenopausal group. The negative correlation of Z-score of lumbar spine BMD with TRAb suggests that this antibody may affect the bone metabolism.
Appendix
Available only for authorised users
Literature
1.
go back to reference Rizzoli R, Poser J, Bürgi U: Nuclear thyroid hormone receptors in cultured bone cells. Metabolism 1986, 35: 71–74.PubMedCrossRef Rizzoli R, Poser J, Bürgi U: Nuclear thyroid hormone receptors in cultured bone cells. Metabolism 1986, 35: 71–74.PubMedCrossRef
2.
go back to reference Coindre JM, David JP, Rivie’Re L, Goussot JF, Roger P, De Mascarel A, Meunier PJ: Bone loss in hyperthyroidism with hormone replacement. Arch Intern Med 1986, 146: 48–53. 10.1001/archinte.1986.00360130058007PubMedCrossRef Coindre JM, David JP, Rivie’Re L, Goussot JF, Roger P, De Mascarel A, Meunier PJ: Bone loss in hyperthyroidism with hormone replacement. Arch Intern Med 1986, 146: 48–53. 10.1001/archinte.1986.00360130058007PubMedCrossRef
3.
go back to reference Britto JM, Fenton AJ, Holloway WR, Nicolson GC: Osteoblasts mediate thyroid hormone stimulation of osteoclastic bone resorption. Endocrinology 1994, 134: 169–176. 10.1210/en.134.1.169PubMed Britto JM, Fenton AJ, Holloway WR, Nicolson GC: Osteoblasts mediate thyroid hormone stimulation of osteoclastic bone resorption. Endocrinology 1994, 134: 169–176. 10.1210/en.134.1.169PubMed
4.
go back to reference Campos-Pastor MM, Munoz-Torres M, Escobar-Jimenez F, Ruiz De Almodovar M, Jodar Gimeno E: Bone mass in females with different thyroid disorders: influence of menopausal status. Bone Miner 1993, 21: 1–82. 10.1016/S0169-6009(08)80115-8PubMedCrossRef Campos-Pastor MM, Munoz-Torres M, Escobar-Jimenez F, Ruiz De Almodovar M, Jodar Gimeno E: Bone mass in females with different thyroid disorders: influence of menopausal status. Bone Miner 1993, 21: 1–82. 10.1016/S0169-6009(08)80115-8PubMedCrossRef
5.
go back to reference Diamond T, Vine J, Smart R, Butler P: Thyrotoxic bone disease in women: a potentially reversible disorder. Ann Intern Med 1994, 120: 8–11. 10.7326/0003-4819-120-1-199401010-00002PubMedCrossRef Diamond T, Vine J, Smart R, Butler P: Thyrotoxic bone disease in women: a potentially reversible disorder. Ann Intern Med 1994, 120: 8–11. 10.7326/0003-4819-120-1-199401010-00002PubMedCrossRef
6.
go back to reference Gomez Acotto C, Schott AM, Hans D, Niepomniszcze H, Mautalen CA, Meunier PJ: Hyperthyroidism influences ultrasound bone measurement on the Os calcis. Osteoporos Int 1998, 8: 455–459. 10.1007/s001980050091PubMedCrossRef Gomez Acotto C, Schott AM, Hans D, Niepomniszcze H, Mautalen CA, Meunier PJ: Hyperthyroidism influences ultrasound bone measurement on the Os calcis. Osteoporos Int 1998, 8: 455–459. 10.1007/s001980050091PubMedCrossRef
7.
go back to reference Olkawa M, Kushida K, Takahashi M, Ohishi T, Hoshino H, Suzuki M, Ogihara H, Ishigaki J, Inoue T: Bone turnover and cortical bone mineral density in the distal radius in patients with hyperthyroidism being treated with antithyroid drugs for various periods of time. Clin Endocrinol (Oxf) 1999, 50: 171–176. 10.1046/j.1365-2265.1999.00626.xCrossRef Olkawa M, Kushida K, Takahashi M, Ohishi T, Hoshino H, Suzuki M, Ogihara H, Ishigaki J, Inoue T: Bone turnover and cortical bone mineral density in the distal radius in patients with hyperthyroidism being treated with antithyroid drugs for various periods of time. Clin Endocrinol (Oxf) 1999, 50: 171–176. 10.1046/j.1365-2265.1999.00626.xCrossRef
8.
go back to reference Mora S, Pitukcheewanont P, Kaufman FR, Nelson JC, Gilsanz V: Biochemical markers of bone turnover and the volume and the density of bone in children at different stages of sexual development. J Bone Miner Res 1999, 14: 1664–1671. 10.1359/jbmr.1999.14.10.1664PubMedCrossRef Mora S, Pitukcheewanont P, Kaufman FR, Nelson JC, Gilsanz V: Biochemical markers of bone turnover and the volume and the density of bone in children at different stages of sexual development. J Bone Miner Res 1999, 14: 1664–1671. 10.1359/jbmr.1999.14.10.1664PubMedCrossRef
9.
go back to reference Ben-Shlomo A, Hagag P, Evans S, Weiss M: Early postmenopausal bone loss in hyperthyroidism. Maturitas 2001, 39: 19–27. 10.1016/S0378-5122(00)00179-1PubMedCrossRef Ben-Shlomo A, Hagag P, Evans S, Weiss M: Early postmenopausal bone loss in hyperthyroidism. Maturitas 2001, 39: 19–27. 10.1016/S0378-5122(00)00179-1PubMedCrossRef
10.
go back to reference Karga H, Papapetrou PD, Korakovouni A, Papandroulaki F, Polymeris A, Pampouras G: Bone mineral density in hyperthyroidism. Clin Endocrinol (Oxf) 2004, 1: 466–472.CrossRef Karga H, Papapetrou PD, Korakovouni A, Papandroulaki F, Polymeris A, Pampouras G: Bone mineral density in hyperthyroidism. Clin Endocrinol (Oxf) 2004, 1: 466–472.CrossRef
11.
go back to reference Mosekilde L, Eriksen EF, Charles P: Effects of thyroid hormones on bone and mineral metabolism. Endocrinol Metab Clin North Am 1990, 19: 35–63.PubMed Mosekilde L, Eriksen EF, Charles P: Effects of thyroid hormones on bone and mineral metabolism. Endocrinol Metab Clin North Am 1990, 19: 35–63.PubMed
12.
go back to reference Jódar E, Muñoz-Torres M, Escobar-Jiménez F, Quesada M, Luna JD, Olea N: Antiresorptive therapy in hyperthyroid patients: longitudinal changes in bone and mineral metabolism. J Clin Endocrinol Metab 1997, 82: 1989–1994. 10.1210/jc.82.6.1989PubMedCrossRef Jódar E, Muñoz-Torres M, Escobar-Jiménez F, Quesada M, Luna JD, Olea N: Antiresorptive therapy in hyperthyroid patients: longitudinal changes in bone and mineral metabolism. J Clin Endocrinol Metab 1997, 82: 1989–1994. 10.1210/jc.82.6.1989PubMedCrossRef
13.
go back to reference Langdahl BL, Loft AGR, Eriksen EF, Mosekilde L, Charles P: Bone mass, bone turnover, body composition, and calcium homeostasis in former hyperthyroid patients treated by combined medical therapy. Thyroid 1996, 6: 161–168.PubMed Langdahl BL, Loft AGR, Eriksen EF, Mosekilde L, Charles P: Bone mass, bone turnover, body composition, and calcium homeostasis in former hyperthyroid patients treated by combined medical therapy. Thyroid 1996, 6: 161–168.PubMed
14.
go back to reference Mudde AH, Houben AJ, Nieuwenhuijzen Kruseman AC: Bone metabolism during anti-thyroid drug treatment of endogenous subclinical hyperthyroidism. Clin Endocrinol (Oxf) 1994, 41: 421–424. 10.1111/j.1365-2265.1994.tb02571.xCrossRef Mudde AH, Houben AJ, Nieuwenhuijzen Kruseman AC: Bone metabolism during anti-thyroid drug treatment of endogenous subclinical hyperthyroidism. Clin Endocrinol (Oxf) 1994, 41: 421–424. 10.1111/j.1365-2265.1994.tb02571.xCrossRef
15.
go back to reference Abe E, Marians RC, Yu W, Wu XB, Ando T, Li Y, Iqbal J, Eldeiry L, Rajendren G, Blair HC, Davies TF, Zaidi M: TSH is a negative regulator of skeletal remodeling. Cell 2003, 115: 151–162. 10.1016/S0092-8674(03)00771-2PubMedCrossRef Abe E, Marians RC, Yu W, Wu XB, Ando T, Li Y, Iqbal J, Eldeiry L, Rajendren G, Blair HC, Davies TF, Zaidi M: TSH is a negative regulator of skeletal remodeling. Cell 2003, 115: 151–162. 10.1016/S0092-8674(03)00771-2PubMedCrossRef
16.
go back to reference Majima T, Komatsu Y, Doi K, Takagi C, Shigemoto M, Fukao A, Morimoto T, Corners J, Nakao K: Negative correlation between bone mineral density and TSH receptor antibodies in male patients with untreated Graves’ disease. Osteoporos Int 2006, 7: 1103–1110.CrossRef Majima T, Komatsu Y, Doi K, Takagi C, Shigemoto M, Fukao A, Morimoto T, Corners J, Nakao K: Negative correlation between bone mineral density and TSH receptor antibodies in male patients with untreated Graves’ disease. Osteoporos Int 2006, 7: 1103–1110.CrossRef
17.
go back to reference Greenspan SL, Greenspan FS, Resnick NM, Block JE, Friedlander AL, Genant HK: Skeletal integrity in premenopausal and postmenopausal women receiving longterm L-thyroxine therapy. Am J Med 1991, 91: 5–14. 10.1016/0002-9343(91)90066-7PubMedCrossRef Greenspan SL, Greenspan FS, Resnick NM, Block JE, Friedlander AL, Genant HK: Skeletal integrity in premenopausal and postmenopausal women receiving longterm L-thyroxine therapy. Am J Med 1991, 91: 5–14. 10.1016/0002-9343(91)90066-7PubMedCrossRef
18.
go back to reference Rees Smith B, McLachlan SM, Furmaniak J: Autoantibodies to the thyrotropin receptor. Endocr Rev 1988,9(1):106–121. 10.1210/edrv-9-1-106PubMedCrossRef Rees Smith B, McLachlan SM, Furmaniak J: Autoantibodies to the thyrotropin receptor. Endocr Rev 1988,9(1):106–121. 10.1210/edrv-9-1-106PubMedCrossRef
19.
go back to reference Takasu N, Oshiro C, Akamine H, Komiya I, Nagata A, Sato Y, Yoshimura H, Ito K: Thyroid-stimulating antibody and TSH-binding inhibitor immunoglobulin in 277 Graves’ patients and in 686 normal subjects. J Endocrinol Invest 1997,20(8):452–461.PubMedCrossRef Takasu N, Oshiro C, Akamine H, Komiya I, Nagata A, Sato Y, Yoshimura H, Ito K: Thyroid-stimulating antibody and TSH-binding inhibitor immunoglobulin in 277 Graves’ patients and in 686 normal subjects. J Endocrinol Invest 1997,20(8):452–461.PubMedCrossRef
20.
go back to reference Gauna AT, Guillén CE, Sartorio GC, Soto RJ: Graves’ disease: evolution and prognosis after eight months of treatment with methimazole. Medicina (B Aires) 1992,52(3):207–212. Gauna AT, Guillén CE, Sartorio GC, Soto RJ: Graves’ disease: evolution and prognosis after eight months of treatment with methimazole. Medicina (B Aires) 1992,52(3):207–212.
21.
go back to reference Eriksen EF: Normal and pathological remodeling of human trabecular bone: three dimensional reconstruction of the remodeling sequence in normals and in metabolic bone disease. Endocr Rev 1986, 7: 379–408. 10.1210/edrv-7-4-379PubMedCrossRef Eriksen EF: Normal and pathological remodeling of human trabecular bone: three dimensional reconstruction of the remodeling sequence in normals and in metabolic bone disease. Endocr Rev 1986, 7: 379–408. 10.1210/edrv-7-4-379PubMedCrossRef
22.
go back to reference Ross DS: Hyperthyroidism, thyroid hormone therapy, and bone. Thyroid 1994, 4: 319–326. 10.1089/thy.1994.4.319PubMedCrossRef Ross DS: Hyperthyroidism, thyroid hormone therapy, and bone. Thyroid 1994, 4: 319–326. 10.1089/thy.1994.4.319PubMedCrossRef
23.
go back to reference Udayakumar N, Chandrasekaran M, Rasheed MH, Suresh RV, Sivaprakash S: Evaluation of bone mineral density in thyrotoxicosis. Singapore Med J 2006,47(11):947–950.PubMed Udayakumar N, Chandrasekaran M, Rasheed MH, Suresh RV, Sivaprakash S: Evaluation of bone mineral density in thyrotoxicosis. Singapore Med J 2006,47(11):947–950.PubMed
24.
go back to reference Nagasaka S, Sugimoto H, Nakamura T, Kusaka I, Fujisawa G, Sakuma N, Tsuboi Y, Fukuda S, Honda K, Okada K, Ishikawa S, Saito T: Antithyroid therapy improves bony manifestations and bone metabolic markers in patients with Graves’ thyrotoxicosis. Clin Endocrinol (Oxf) 1997,47(2):215–221. 10.1046/j.1365-2265.1997.2401045.xCrossRef Nagasaka S, Sugimoto H, Nakamura T, Kusaka I, Fujisawa G, Sakuma N, Tsuboi Y, Fukuda S, Honda K, Okada K, Ishikawa S, Saito T: Antithyroid therapy improves bony manifestations and bone metabolic markers in patients with Graves’ thyrotoxicosis. Clin Endocrinol (Oxf) 1997,47(2):215–221. 10.1046/j.1365-2265.1997.2401045.xCrossRef
25.
go back to reference Grant DJ, McMurdo ME, Mole PA, Paterson CR: Is previous hyperthyroidism still a risk factor for osteoporosis in post-menopausal women? Clin Endocrinol (Oxf) 1995,43(3):339–345. 10.1111/j.1365-2265.1995.tb02041.xCrossRef Grant DJ, McMurdo ME, Mole PA, Paterson CR: Is previous hyperthyroidism still a risk factor for osteoporosis in post-menopausal women? Clin Endocrinol (Oxf) 1995,43(3):339–345. 10.1111/j.1365-2265.1995.tb02041.xCrossRef
26.
go back to reference Krølner B, Jørgensen JV, Nielsen SP: Spinal bone mineral content in myxoedema and thyrotoxicosis. effects of thyroid hormone(s) and antithyroid treatment. Clin Endocrinol (Oxf) 1983,18(5):439–446. 10.1111/j.1365-2265.1983.tb02873.xCrossRef Krølner B, Jørgensen JV, Nielsen SP: Spinal bone mineral content in myxoedema and thyrotoxicosis. effects of thyroid hormone(s) and antithyroid treatment. Clin Endocrinol (Oxf) 1983,18(5):439–446. 10.1111/j.1365-2265.1983.tb02873.xCrossRef
27.
go back to reference Rosen CJ, Adler RA: Longitudinal changes in lumbar bone density among thyrotoxic patients after attainment of euthyroidism. J Clin Endocrinol Metab 1992,75(6):1531–1534. 10.1210/jc.75.6.1531PubMed Rosen CJ, Adler RA: Longitudinal changes in lumbar bone density among thyrotoxic patients after attainment of euthyroidism. J Clin Endocrinol Metab 1992,75(6):1531–1534. 10.1210/jc.75.6.1531PubMed
28.
go back to reference Cummings SR, Nevitt MC, Browner WS, Stone K, Fox KM, Ensrud KE, Cauley J, Black D, Vogt TM: Risk factors for hip fracture in white women. study of osteoporotic fractures research group. N Engl J Med 1995,23(12):767–773.CrossRef Cummings SR, Nevitt MC, Browner WS, Stone K, Fox KM, Ensrud KE, Cauley J, Black D, Vogt TM: Risk factors for hip fracture in white women. study of osteoporotic fractures research group. N Engl J Med 1995,23(12):767–773.CrossRef
29.
go back to reference Wejda B, Hintze G, Katschinski B, Olbricht T, Benker G: Hip fractures and the thyroid: a case–control study. J Intern Med 1995,237(3):241–247. 10.1111/j.1365-2796.1995.tb01172.xPubMedCrossRef Wejda B, Hintze G, Katschinski B, Olbricht T, Benker G: Hip fractures and the thyroid: a case–control study. J Intern Med 1995,237(3):241–247. 10.1111/j.1365-2796.1995.tb01172.xPubMedCrossRef
30.
go back to reference Vestergaard P, Rejnmark L, Weeke J, Mosekilde L: Fracture risk in patients treated for hyperthyroidism. Thyroid 2000,10(4):341–348. 10.1089/thy.2000.10.341PubMedCrossRef Vestergaard P, Rejnmark L, Weeke J, Mosekilde L: Fracture risk in patients treated for hyperthyroidism. Thyroid 2000,10(4):341–348. 10.1089/thy.2000.10.341PubMedCrossRef
31.
go back to reference Vestergaard P, Mosekilde L: Fractures in patients with hyperthyroidism and hypothyroidism: a nationwide follow-up study in 16,249 patients. Thyroid 2002,12(5):411–419. 10.1089/105072502760043503PubMedCrossRef Vestergaard P, Mosekilde L: Fractures in patients with hyperthyroidism and hypothyroidism: a nationwide follow-up study in 16,249 patients. Thyroid 2002,12(5):411–419. 10.1089/105072502760043503PubMedCrossRef
32.
go back to reference Solomon BL, Wartofsky L, Burman KD: Prevalence of fractures in postmenopausal women with thyroid disease. Thyroid 1993,3(1):17–23. 10.1089/thy.1993.3.17PubMedCrossRef Solomon BL, Wartofsky L, Burman KD: Prevalence of fractures in postmenopausal women with thyroid disease. Thyroid 1993,3(1):17–23. 10.1089/thy.1993.3.17PubMedCrossRef
33.
go back to reference Faber J, Jensen IW, Petersen L, Nygaard B, Hegedüs L, Siersbaek-Nielsen K: Normalization of serum thyrotrophin by means of radioiodine treatment in subclinical hyperthyroidism: effect on bone loss in postmenopausal women. Clin Endocrinol (Oxf) 1998,48(3):285–290. 10.1046/j.1365-2265.1998.00427.xCrossRef Faber J, Jensen IW, Petersen L, Nygaard B, Hegedüs L, Siersbaek-Nielsen K: Normalization of serum thyrotrophin by means of radioiodine treatment in subclinical hyperthyroidism: effect on bone loss in postmenopausal women. Clin Endocrinol (Oxf) 1998,48(3):285–290. 10.1046/j.1365-2265.1998.00427.xCrossRef
34.
go back to reference Finkelstein JS, Brockwell SE, Mehta V, Greendale GA, Sowers MR, Ettinger B, Lo JC, Johnston JM, Cauley JA, Danielson ME, Neer RM: Bone mineral density changes during the menopause transition in a multiethnic cohort of women. J Clin Endocrinol Metab 2008,93(3):861–868.PubMedCentralPubMedCrossRef Finkelstein JS, Brockwell SE, Mehta V, Greendale GA, Sowers MR, Ettinger B, Lo JC, Johnston JM, Cauley JA, Danielson ME, Neer RM: Bone mineral density changes during the menopause transition in a multiethnic cohort of women. J Clin Endocrinol Metab 2008,93(3):861–868.PubMedCentralPubMedCrossRef
35.
go back to reference Kumeda Y, Inaba M, Tahara H, Kurioka Y, Ishikawa T, Morii H, Nishizawa Y: Persistent increase in bone turnover in Graves’ patients with subclinical hyperthyroidism. J Clin Endocrinol Metab 2000,85(11):4157–4161. 10.1210/jc.85.11.4157PubMed Kumeda Y, Inaba M, Tahara H, Kurioka Y, Ishikawa T, Morii H, Nishizawa Y: Persistent increase in bone turnover in Graves’ patients with subclinical hyperthyroidism. J Clin Endocrinol Metab 2000,85(11):4157–4161. 10.1210/jc.85.11.4157PubMed
36.
go back to reference Mizutori Y, Chen CR, Latrofa F, McLachlan SM, Rapoport B: Evidence that shed thyrotropin receptor A subunits drive affinity maturation of autoantibodies causing Graves’ disease. J Clin Endocrinol Metab 2009,94(3):927–935.PubMedCentralPubMedCrossRef Mizutori Y, Chen CR, Latrofa F, McLachlan SM, Rapoport B: Evidence that shed thyrotropin receptor A subunits drive affinity maturation of autoantibodies causing Graves’ disease. J Clin Endocrinol Metab 2009,94(3):927–935.PubMedCentralPubMedCrossRef
37.
go back to reference Weetman AP, McGregor AM: Autoimmune thyroid disease: further developments in our understanding. Endocr Rev 1994, 15: 788–830.PubMed Weetman AP, McGregor AM: Autoimmune thyroid disease: further developments in our understanding. Endocr Rev 1994, 15: 788–830.PubMed
38.
go back to reference Ando T, Latif R, Davies TF: Concentration-dependent regulation of thyrotropin receptor function by thyroid-stimulating antibody. J Clin Inv 2004,113(11):189–195.CrossRef Ando T, Latif R, Davies TF: Concentration-dependent regulation of thyrotropin receptor function by thyroid-stimulating antibody. J Clin Inv 2004,113(11):189–195.CrossRef
39.
go back to reference Belsing TZ, Tofteng C, Langdahl BL, Charles P, Feldt-Rasmussen U: Can bone loss be reversed by antithyroid drug therapy in premenopausal women with Graves’ disease? Nutr Metab (Lond) 2010,1(7):72–81.CrossRef Belsing TZ, Tofteng C, Langdahl BL, Charles P, Feldt-Rasmussen U: Can bone loss be reversed by antithyroid drug therapy in premenopausal women with Graves’ disease? Nutr Metab (Lond) 2010,1(7):72–81.CrossRef
40.
go back to reference Morimura T, Tsunekawa K, Kasahara T, Seki K, Ogiwara T, Mori M, Murakami M: Expression of type 2 iodothyronine deiodinase in human osteoblast is stimulated by thyrotropin. Endocrinology 2005,146(4):2077–2084. 10.1210/en.2004-1432PubMedCrossRef Morimura T, Tsunekawa K, Kasahara T, Seki K, Ogiwara T, Mori M, Murakami M: Expression of type 2 iodothyronine deiodinase in human osteoblast is stimulated by thyrotropin. Endocrinology 2005,146(4):2077–2084. 10.1210/en.2004-1432PubMedCrossRef
41.
go back to reference Torring O, Tallstedt L, Wallin G, Lundell G, Ljunggren JG, Taube A, Saaf M, Hamberger B: Graves’ hyperthyroidism: treatment with antithyroid drugs, surgery, or radioiodine–a prospective, randomized study. thyroid study group. J Clin Endocrinol Metab 1996, 81: 2986–2993. 10.1210/jc.81.8.2986PubMed Torring O, Tallstedt L, Wallin G, Lundell G, Ljunggren JG, Taube A, Saaf M, Hamberger B: Graves’ hyperthyroidism: treatment with antithyroid drugs, surgery, or radioiodine–a prospective, randomized study. thyroid study group. J Clin Endocrinol Metab 1996, 81: 2986–2993. 10.1210/jc.81.8.2986PubMed
42.
go back to reference Laurberg P, Wallin G, Tallstedt L, Abraham-Nordling M, Lundell G, Tørring O: TSH-receptor autoimmunity in Grave’ disease after therapy with anti-thyroid drugs, surgery, or radioiodine: a 5-year prospective randomized study. Eur J Endocrinol 2008,158(1):69–75. 10.1530/EJE-07-0450PubMedCrossRef Laurberg P, Wallin G, Tallstedt L, Abraham-Nordling M, Lundell G, Tørring O: TSH-receptor autoimmunity in Grave’ disease after therapy with anti-thyroid drugs, surgery, or radioiodine: a 5-year prospective randomized study. Eur J Endocrinol 2008,158(1):69–75. 10.1530/EJE-07-0450PubMedCrossRef
43.
go back to reference Duncan Bassett JH, Williams GR: The molecular actions of thyroid hormone in bone. TRENDS Endocrinol Metab 2003,14(8):356–364. 10.1016/S1043-2760(03)00144-9CrossRef Duncan Bassett JH, Williams GR: The molecular actions of thyroid hormone in bone. TRENDS Endocrinol Metab 2003,14(8):356–364. 10.1016/S1043-2760(03)00144-9CrossRef
44.
go back to reference Martini G, Gennari L, De Paola V, Pilli T, Salvadori S, Merlotti D, Valleggi F, Stella C, Franci B, Nuti AA, Pacini F: The effects of recombinant TSH on bone turnover markers and serum osteoprotegerin and RANKL levels. Thyroid 2008,18(4):455–460. 10.1089/thy.2007.0166PubMedCrossRef Martini G, Gennari L, De Paola V, Pilli T, Salvadori S, Merlotti D, Valleggi F, Stella C, Franci B, Nuti AA, Pacini F: The effects of recombinant TSH on bone turnover markers and serum osteoprotegerin and RANKL levels. Thyroid 2008,18(4):455–460. 10.1089/thy.2007.0166PubMedCrossRef
45.
go back to reference Takasu N, Matsushita M: Changes of TSH-stimulation blocking antibody (TSBAb) and thyroid stimulating antibody (TSAb) over 10 years in 34 TSBAb-positive patients with hypothyroidism and in 98 TSAb-positive Graves’ patients with hyperthyroidism: reevaluation of TSBAb and TSAb in TSH-receptor-antibody (TRAb)-positive patients. J Thyroid Res 2012, 2012: 1–11.CrossRef Takasu N, Matsushita M: Changes of TSH-stimulation blocking antibody (TSBAb) and thyroid stimulating antibody (TSAb) over 10 years in 34 TSBAb-positive patients with hypothyroidism and in 98 TSAb-positive Graves’ patients with hyperthyroidism: reevaluation of TSBAb and TSAb in TSH-receptor-antibody (TRAb)-positive patients. J Thyroid Res 2012, 2012: 1–11.CrossRef
46.
go back to reference Barbesino G, Tomer Y: Clinical review: clinical utility of TSH receptor antibodies. J Clin Endocrinol Metab 2013,98(6):2247–2255. 10.1210/jc.2012-4309PubMedCentralPubMedCrossRef Barbesino G, Tomer Y: Clinical review: clinical utility of TSH receptor antibodies. J Clin Endocrinol Metab 2013,98(6):2247–2255. 10.1210/jc.2012-4309PubMedCentralPubMedCrossRef
Metadata
Title
Negative correlation between bone mineral density and TSH receptor antibodies in long-term euthyroid postmenopausal women with treated Graves’ disease
Authors
Monica A Ercolano
Monica L Drnovsek
Maria C Silva Croome
Monica Moos
Ana M Fuentes
Fanny Viale
Ulla Feldt-Rasmussen
Alicia T Gauna
Publication date
01-12-2013
Publisher
BioMed Central
Published in
Thyroid Research / Issue 1/2013
Electronic ISSN: 1756-6614
DOI
https://doi.org/10.1186/1756-6614-6-11

Other articles of this Issue 1/2013

Thyroid Research 1/2013 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.